Volume 16, Number 2, June 2004

Combination Therapy of Superselective Intra-arterial Nedaplatin Infusion and Radiation Therapy for Oral Cancer

Yoshio Yamashita, Masaaki Goto

Department of Oral and Maxillofacial Surgery, Saga Medical School, Saga, Japan

Objective: Nedaplatin, which is a cisplatin-derivative, has been reported to be an effective anti-tumour agent for head and neck cancer. The purpose of this study was to address the feasibility of a combination of radiotherapy with superselective intra-arterial therapy using nedaplatin in patients with oral cancer.
Patients and Methods: Fourteen patients with oral cancer were treated with chemotherapy by superselective intra-arterial infusion of nedaplatin (90 to 100 mg/m2) combined with concurrent radiation therapy (30 Gy). After evaluation, patients underwent surgery as a therapeutic procedure (resection of the primary tumour and/or the neck).
Results: Complete and partial response rates were achieved by 8 patients (57.2%) and 6 patients (42.8%), respectively. Histological effects classified according to Oboshi-Shimosato's criteria were grade IV in 5 patients, grade IIb in 5, grade IIa in 3, and grade I in 1. Grade IV mucositis was observed in 3 patients (21.4%). All patients were free from renal dysfunction, which is one of the adverse effects of cisplatin. After a median follow-up of 24 months, the locoreginal control rate was 100%.
Conclusion: The results indicate that a combination therapy of superselective intra-arterial nedaplatin infusion and radiation therapy can be delivered safely with good efficacy for locoregional management of oral cancer.

Key words: Chemotherapy, Infusion, Oral cancer, Radiotherapy

Asian J Oral Maxillofac Surg. 2004;16:97-102.
Respond to this article

Powered by JoomlaCommentCopyright (C) 2006 Frantisek Hliva. All rights reserved.Homepage: http://cavo.co.nr/